Display options
Share it on

World J Nucl Med. 2016 Sep;15(3):203-5. doi: 10.4103/1450-1147.172303.

Use of Marrow Scintigraphy to Confirm Compensatory Marrow Rather than Active Myeloma.

World journal of nuclear medicine

Twyla B Bartel, Tracy L Yarbrough, Lorraine E De Blanche

Affiliations

  1. Global Advanced Imaging, PLLC, Little Rock, Arkansas, USA.
  2. Central Arkansas Radiation Therapy Institute, Little Rock, Arkansas, USA.

PMID: 27651743 PMCID: PMC5020796 DOI: 10.4103/1450-1147.172303

Abstract

We present the case of a 40-year-old male with multiple myeloma for whom bone marrow scintigraphy was utilized to help differentiate between active bony myelomatous disease versus treated lesions with compensatory marrow uptake. This case demonstrates technetium (Tc-99m) sulfur colloid imaging as an inexpensive technique to quickly distinguish between active focal bone disease and reactive marrow.

Keywords: Fluorodeoxyglucose; marrow scintigraphy; multiple myeloma; plasmacytoma

Conflict of interest statement

Conflicts of Interest: None declared.

References

  1. Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):166-78 - PubMed
  2. Eur J Nucl Med. 1989;15(5):230-8 - PubMed
  3. Radiol Med. 1988 Oct;76(4):311-5 - PubMed
  4. J Nucl Med. 1979 May;20(5):379-86 - PubMed
  5. Nucl Med Commun. 2008 Jun;29(6):542-5 - PubMed
  6. Semin Nucl Med. 1985 Jul;15(3):239-59 - PubMed
  7. J Nucl Med. 1974 May;15(5):343-8 - PubMed

Publication Types